LIVE WEBINAR
Thursday, November 6th | 2pm ET
Duration: 1 hour
Can't make the live date? Register and we'll send you a link to the recording.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) is underdiagnosed, difficult to identify, and limited in treatment options. Research studies and clinical trials for MASH are challenged in identifying and matching with qualified patients. But now, a clinical study with deep genetic and longitudinal clinical insights has the potential to be a blueprint for developing research studies across a range of disease areas.
This webinar explores how the MASH study, conducted in collaboration between Helix and Renown Health, Nevada’s largest not-for-profit integrated healthcare network, outlines protocols for an easier pathway to personalized medicine. Panelists will discuss the study’s research outcomes and how curated clinico-genomic data can help identify potential therapeutic targets and at-risk patient populations to drive precision medicine development for liver and metabolic conditions. Highlights include:
SPEAKERS
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. | Privacy Policy | Terms of Use